Why the study?
Catheter-based slow-pathway modification is the treatment of choice for symptomatic AVNRT, but the interactions between patient age and procedural outcomes in pediatric patients remained unclear.
Does patient age impact AVNRT recurrence in pediatric patients undergoing catheter-based slow-pathway modification?
Population
512 pediatric patients undergoing successful SPM for AVNRT
Comparison
Patients stratified by age quartile at time of SPM
Design
Retrospective cohort study
Follow-up
Median 0.8 years (interquartile range, 0.2-2.5 years)
Authors
Loading...
Supports safety of slow-pathway modification across pediatric ages; leaves open prospective confirmation of age-independent outcomes.
Does patient age impact AVNRT recurrence in pediatric patients undergoing catheter-based slow-pathway modification?
Radiofrequency slow-pathway modification is highly effective and safe for pediatric AVNRT across age groups, with the youngest patients not facing a higher risk of recurrence.
O’Leary et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: